An observational study in Leukemia, Lymphoid, sponsored by Sichuan University. Not yet recruiting. Open to participants aged 16 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-10-10.
Sponsored by Sichuan University · Observational
The goal of this observation study is to test in relapsed or refractory acute lymphoblastic leukemia (R/R ALL) patients undergoing allogeneic hemopoietic stem-cell transplantation (allo-HSCT). The main question it aims to answer is:
Participants will undergo immune repertoire sequencing(IR-SEQ) before blinatumomab treatment, 6 months and 1 year after transplantation.
Researchers will compare patients who don't receive blinatumomab treatment after transplantation to see if TCR or BCR expression differs.
1,780 studies on the registry are indexed under Leukemia, Lymphoid; 176 are open to participants now.
This study's planned enrollment of 20 is below the median of 112 across 227 observational studies indexed under Leukemia, Lymphoid.
Browse Leukemia, Lymphoid studies →Sichuan University is the lead sponsor of 106 studies on the registry; 65 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Relapsed or refractory acute lymphoblastic leukemia (R/R ALL) patients undergoing allogeneic hemopoietic stem-cell transplantation (allo-HSCT).
Exclusion Criteria:
Post-transplant cyclophosphamide is used as graft versus host disease (GvHD) prophylaxis. Treatment with blinatumomab was initiated within 60 to 90 days after transplantation and was administered bimonthly until 1 year after transplantation.
Drug: blinatumomab
Antithymocyte globulin is used as graft versus host disease (GvHD) prophylaxis. Treatment with blinatumomab was initiated within 60 to 90 days after transplantation and was administered bimonthly until 1 year after transplantation.
Drug: blinatumomab
Patients don't take blinatumomab treatment after transplantation.
The dose of one course was as follows: day 1-2: 8ug/day, continuous intravenous drip for 24 hours, day 3-7: 16ug/day, continuous intravenous drip for 24 hours. Treatment with blinatumomab was initiated within 60 to 90 days after transplantation and was administered bimonthly until 1 year after transplantation. Dexamethasone 20mg was administered 1 hour before administration on days 1 and 3 to prevent adverse events.
T cell receptor expression
T cell receptor expression measured by Immune Repertoire sequencing(IR-SEQ)
Time frame: before blinatumomab treatment , 6 months and 1 year
B cell receptor expression
B cell receptor expression measured by Immune Repertoire sequencing(IR-SEQ)
Time frame: before blinatumomab treatment , 6 months and 1 year
T cell subsets count
T cell subsets count including CD3+, CD4+, CD8+, CD19+, Treg, memory and cytotoxic T cells
Time frame: before blinatumomab treatment , 6 months and 1 year
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sichuan University